The MIGHT Study: Testing IVIG for a Specific Muscle Weakness Condition
The MIGHT Trial - An Exploratory Clinical Trial of IVIG in anti-HMGCR ImmuneMediated Necrotizing Myopathy
This study is testing a treatment called IVIG for people with a specific muscle weakness condition called anti-HMGCR immune-mediated necrotizing myopathy.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-11170469 on NIH RePORTER |
What this research studies
This research focuses on a severe muscle weakness condition called anti-HMGCR immune-mediated necrotizing myopathy, which currently lacks specific proven treatments. We want to find out if a treatment called IVIG, which is a type of immune globulin given through a vein, can help improve muscle strength and reduce disability for patients. While observational information suggests IVIG might be helpful, this study will be a pilot clinical trial to formally test its effectiveness against a placebo. We also hope to learn more about how the immune system causes this condition and how IVIG might work to improve it.
Who could benefit from this research
Good fit: Ideal candidates are adults aged 21 and older who have been diagnosed with anti-HMGCR immune-mediated necrotizing myopathy.
Not a fit: Patients without anti-HMGCR immune-mediated necrotizing myopathy or those who do not meet the age criteria would not receive direct benefit from participating in this specific study.
Why it matters
Potential benefit: If successful, this study could establish IVIG as an effective treatment for anti-HMGCR IMNM, offering a new option to improve muscle strength and reduce disability.
How similar studies have performed: While no placebo-controlled trials for anti-HMGCR IMNM have been completed, observational evidence strongly suggests that IVIG may be effective, making this a crucial next step.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Andrews, James — University of Alabama at Birmingham
- Study coordinator: Andrews, James
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.